Tau Pathology plays an important role in the study of neurodegenerative . This page provides comprehensive information about this topic, including its , significance in disease processes, and therapeutic implications.
tau-protein Pathology is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes 45 sites, approximately 3-4 fold more than normal tau. Key pathological sites:
| Site | Antibody/Epitope | Significance |
|------|-----------------|-------------|
| Ser202/Thr205 | AT8 | Most commonly used diagnostic marker; early phosphorylation event |
| Thr181 | AT270 | CSF p-tau181 biomarker |
| Thr217 | — | [p-tau217](/biomarkers/p-tau-217) — most accurate blood-based AD biomarker |
| Thr231 | AT180 | p-tau231 — earliest CSF change; reflects amyloid-beta-driven tau phosphorylation |
| Ser396/Ser404 | PHF-1 | late-stage phosphorylation; correlates with tangle maturity |
| Ser262 | 12E8 | Within KXGS motif in repeat domain; directly reduces MT binding |
Tau Pathology plays an important role in the study of neurodegenerative . This page provides comprehensive information about this topic, including its , significance in disease processes, and therapeutic implications.
tau-protein Pathology is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes 45 sites, approximately 3-4 fold more than normal tau. Key pathological sites:
| Site | Antibody/Epitope | Significance |
|------|-----------------|-------------|
| Ser202/Thr205 | AT8 | Most commonly used diagnostic marker; early phosphorylation event |
| Thr181 | AT270 | CSF p-tau181 biomarker |
| Thr217 | — | [p-tau217](/biomarkers/p-tau-217) — most accurate blood-based AD biomarker |
| Thr231 | AT180 | p-tau231 — earliest CSF change; reflects amyloid-beta-driven tau phosphorylation |
| Ser396/Ser404 | PHF-1 | late-stage phosphorylation; correlates with tangle maturity |
| Ser262 | 12E8 | Within KXGS motif in repeat domain; directly reduces MT binding |
Major tau kinases (hyperphosphorylation drivers):
style TAU fill:#e3f2fd,stroke:#1565c0
style PHOS fill:#fff3e0,stroke:#e65100
style OLIGO fill:#fce4ec,stroke:#c62828
style PHF fill:#f3e5f5,stroke:#6a1b9a
style NFT fill:#f3e5f5,stroke:#6a1b9a
style GHOST fill:#efebe9,stroke:#4e342e
style SPREAD fill:#fff3e0,stroke:#e65100
```
Tau oligomers are now considered the most neurotoxic species, preceding fibril formation and correlating with synaptic-dysfunction, mitochondrial damage, and membrane disruption.
A transformative advance: cryo-EM has revealed that each tauopathy has a unique tau filament fold (Fitzpatrick et al., 2017):
| Disease | Filament Type | Tau Isoforms | Core Residues | Key Structural Feature |
|---------|--------------|-------------|---------------|----------------------|
| AD | PHF and SF | 3R+4R | R3-R4 (306-378) | C-shaped fold; β-helix |
| Pick's disease | Pick body filaments | 3R | R1, R3-R4 | Elongated J-shape |
| CBD | CBD filaments | 4R | R1-R4 (274-380) | Four-layered; distinctive β-arch |
| PSP | PSP filaments | 4R | R1-R4 (272-381) | Distinct from CBD despite 4R overlap |
| CTE | CTE filaments | 3R+4R | R3-R4 | Unique hydrophobic cavity |
| AGD | AGD filaments | 4R | Similar to PSP | Closely related to PSP fold |
| GGT | GGT filaments | 4R | R2-R4 | Distinct glial tauopathy |
These structures demonstrate that the same tau protein]//tau adopts disease-specific conformations, supporting the concept of prion-like conformational strains [@longitudinal].
Tau pathology follows a stereotypical progression through defined brain regions (Braak & Braak, 1991):
| Braak Stage | Regions Affected | Clinical Correlation | Tau PET Pattern |
|-------------|-----------------|---------------------|-----------------|
| I-II (Transentorhinal) | Entorhinal [cortex, transentorhinal region | Clinically silent; pre-symptomatic | Medial temporal positivity |
| III-IV (Limbic) | hippocampus, amygdala, limbic cortex | Mild cognitive impairment (MCI) | Temporal and parietal spread |
| V-VI (Neocortical) | Association cortices → primary cortices | Moderate to severe dementia | Widespread cortical uptake |
The Braak staging pattern is now detectable in living patients using tau PET imaging (flortaucipir/18FMK-6240), enabling in vivo staging of AD 90% accuracy for AD diagnosis; approaching CSF performance
| Antibody | Target | Status (2025) | Key Results |
|----------|--------|---------------|-------------|
| Semorinemab | N-terminal tau (extracellular) | Phase 2 completed | No cognitive benefit in prodromal AD; modest effect in mild-moderate AD |
| Bepranemab | Mid-domain tau | Phase 2 | Slowed tau PET accumulation by ~60%; cognition data pending |
| E2814 | MTBR tau (seed-competent) | Phase 2/3 (DIAN
| JNJ-63733657 | p-tau217 | Phase 2 | Reduced CSF p-tau217 by >90% |
| Zagotenemab | Conformational tau | Phase 2 completed | Did not meet primary endpoints |
The study of Tau Pathology has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [ of neurodegeneration and continues to drive therapeutic development [@antibodies].
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [^6].
Tau pathology is not specific to alzheimers but occurs in several other neurodegenerative conditions:
These share common pathogenetic including:
Cerebrospinal fluid provide information about tau pathology:
Multiple anti-tau therapies are in various stages of clinical development, targeting:
Tau pathology represents one of the most critical hallmarks of alzheimers and several other neurodegenerative conditions collectively known as tauopathies. The tau protein, encoded by the mapt (tau-protein gene on chromosome 17q21.31, plays essential roles in neuronal function under normal conditions but undergoes pathological transformations that contribute to neurodegeneration.
The following resources provide additional data on tau protein and related genes:
Recent structural and assay developments in tau pathology] sharpen how conformational diversity, mutation-specific folding, and seeding competence are measured across alzheimers and related tauopathies.
!Annotated neurofibrillary tangles in Alzheimer's Disease
This histology image shows annotated neurofibrillary tangles relevant to Tau(//tau, alzheimers, and tauopathy progression staging.
Image attribution: Mikael Haggstrom, Histopathology of neurofibrillary tangles in Alzheimer's Disease - annotated (CC0)(https://commons.wikimedia.org/wiki/File:Histopathology_of_neurofibrillary_tangles_in_Alzheimer%27s_disease_-_annotated.jpg)
Tau Biomarker-Based Diagnosis: Nelson and Jicha<a href="#references" class="ref-link" data-ref-text="Nelson & Jicha, Tau Biomarker-Based Diagnosis of Alzheimer's Disease. Neurology (2026)">X</a> analyze tau biomarker-based diagnosis of Alzheimer's Disease and the relationship between tau pathology and the anti-[amyloid-beta therapeutic window. This research advances precision medicine approaches for AD diagnosis and treatment selection.
<!-- ci040-visuals:tau-aggregation -->
!tau-aggregation pathway diagram["/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg"
Figure: tau aggregation pathway schematic generated for NeuroWiki.
F-18 TKH5105 selectively binds to pathological PHF tau deposition in living AD patients and differentiates diseased brains from healthy controls. AD patients showed high retention in temporal cortex (known high density of neurofibrillary tangles) compared to cerebellum. Healthy controls' uptake in inferior temporal cortex was identical to cerebellum activity. Also showed in vitro binding to glial tau pathology in corticobasal degeneration and PSP. Rapid entry into gray matter areas, no toxic events reported.
Model System: Human subjects - patients with Alzheimer's disease (n=not specified) and healthy controls
Statistical Significance: Not reported
James et al., (2015)
FDDNP demonstrates binding to both beta-amyloid and tau pathology (was not designed as specific tau tracer)
Model System: Human subjects
Statistical Significance: Not reported
James et al., (2015)
AD patients have significantly higher tau tracer retention than CN individuals. Binding in inferior lateral temporal, posterior cingulate, and lateral parietal regions matches known regional deposition of tau pathology. In atypical AD presentations, spatial pattern of retention matches underlying clinical phenotypes.
Model System: AD patients (prodromal and dementia stages)
Statistical Significance: p<0.05 for group differences between AD and CN
Leuzy et al., (2019)
Regional pattern of tau pathology expected in these with relatively good discrimination from healthy volunteers. However, many ROIs coincide with areas showing off-target binding to MAO-B in basal ganglia, creating overlap across diagnostic groups. Longitudinal imaging shows increase in tracer binding with disease progression.
Model System: Patients with clinical diagnoses of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)
Statistical Significance: Tracer binding correlates with clinical scores of functional impairment in PSP
Leuzy et al., (2019)
Normal aging leads to increases in H4K16ac; AD associated with H4K16ac loss in lateral temporal lobe including near AD susceptibility loci. Tau pathology correlates with H3K9ac dysregulation in up to 23% of all H3K9ac domains. Tau-related H3K9ac alterations cluster in large genomic segments covering several megabase pairs.
Model System: Human AD postmortem brain (lateral temporal lobe, [entorhinal cortex](/brain-regions/entorhinal-cortex), dorsolateral prefrontal cortex)
Statistical Significance: Not specified
Cláudio Gouveia Roque et al., (2024)
All three subjects had intermediate to high AD neuropathological change. Braak stages: Case 1 (VI/V), Case 2 (IV/V), Case 3 (V/V). Thal phases: Cases 1 and 3 = 4 (high), Case 2 = 3 (intermediate). CERAD: Cases 1 and 3 frequent, Case 2 moderate. No atypical tau pathology identified in any case.
Model System: Human postmortem brain tissue
Statistical Significance: N/A - descriptive neuropathology
Pontecorvo et al., (2020)
Strong evidence that tau PET tracers (18F-flortaucipir, 18F-MK6240, 18F-RO948, 18F-PI2620) bind AD tau aggregates in advanced Braak stages (>IV). Accuracy for detecting tau load in Braak V-VI was 87.5% (95% CI, 77.2%-93.5%). Strong correlations (R2 range, 0.66-0.76) between tau PET levels and quantitative neuropathologic tau burden. Tracer binding weaker in non-AD tauopathies and overlaps with off-target regions.
Model System: Human postmortem brain tissue
Statistical Significance: R2 range 0.66-0.76 for AD tau correlations; 87.5% accuracy for Braak V-VI detection
Groot et al., (2022)
Flortaucipir PET predicted B3-level tau pathology with sensitivity 92.3-100% and specificity 52.0-92.0%. Predicted high ADNC with sensitivity 94.7-100% and specificity 50.0-92.3%. Majority read analysis showed 92.3% sensitivity and 80.0% specificity for B3, 94.7% sensitivity and 80.8% specificity for high ADNC. Inter-rater reliability high (Fleiss k=0.74, P<.001). SUVR cutpoint >1.113 yielded 84.2% sensitivity for B3 and 86.5% for high ADNC with 100% specificity.
Model System: Human participants with terminal illness (n=64 in primary cohort; 156 enrolled total; 67 autopsied)
Statistical Significance: P<.001 for inter-rater reliability; 95% CI ranges provided for all sensitivity/specificity values
Fleisher et al., (2020)
Tau pathology appears in [hippocampus](/brain-regions/hippocampus), parahippocampus, and entorhinal cortex in early dementia stages. Increased tau in inferior temporal lobe associated with worse memory. CSF tau levels correlated with tau imaging in 6 brain regions consistent with Braak staging. Test/retest reproducibility ~4-5%. ~10% year-over-year increase in mean cortical SUVR in high amyloid burden subjects. Increased tau accompanied by lower MMSE performance.
Model System: Human subjects from Harvard Aging Brain Study (75 older subjects)
Statistical Significance: Statistically significant correlations between CSF tau and tau PET in entorhinal/parahippocampal regions, inferior temporal, middle temporal, and superior temporal cortices
Hartmuth C. Kolb, José Ignacio Andrés (2017)
T807 perfectly colocalized with tau-containing neurons/neurons) and dystrophic neurites. Confirmed strong T807 binding to tau pathology in AD but not to cerebral amyloid, DLB, MSA, or [TDP-43](/mechanisms/tdp-43-proteinopathy). Tangles and dystrophic neurites account for most of the in vivo T807 signal.
Model System: Human AD brain tissue
Statistical Significance: N/A
Hartmuth C. Kolb, José Ignacio Andrés (2017)
Cases showed: (1) pathology often exists around the periphery of amygdalae near meninges and/or lateral ventricle; (2) peri-amygdaloid grey matter including entorhinal cortex frequently shows pathologies; (3) cortical and transitional regions are vulnerable; (4) phospho-Tau pathology is constant in all aged individuals. Cases 3-6 showed comorbid Ab, Tau, a-synuclein, and TDP-43 pathologies.
Model System: Human postmortem amygdala tissue (UK-ADC autopsy cohort)
Statistical Significance: Not applicable (descriptive case series)
Nelson et al., (2018)
p-tau begins to accumulate in LC early in life, in some cases as young as 10 years of age; 90% of individuals have some tau pathology in LC by age 30; 72% of individuals aged 31-40 years have tau lesions; 94% of individuals aged 41-50 years have tau lesions
Model System: Human postmortem brain tissue
Statistical Significance: Not reported
Matchett et al., (2021)
Additional evidence sources: [@shortlived] [@bloodbased] [@association] [^8] [^9] [^10] [^11] [^12] [@stern2026] [@kumar2026] [@pourshafie2026] [@mcdade2025]
This section highlights recent publications relevant to this mechanism.
[@roemercassiano2025]: Roemer-Cassiano SN et al., Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease. Brain (2025).
[@welikovitch2025]: Welikovitch LA et al., Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-beta immunotherapy. Nat Commun (2025).
[@arnsten2025]: Arnsten AFT et al., An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease. Nat Rev Immunol (2025).
[@hou2025]: Hou K et al., How short peptides disassemble tau fibrils in Alzheimer's disease. Nat Commun (2025).
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 25 references |
| Replication | 33% |
| Effect Sizes | 75% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 65%